The document discusses diffuse large B-cell lymphoma (DLBCL), its subtypes and classification. It describes how DLBCL can be categorized based on site of origin, characteristic features, association with viruses, or remain unclassified. Gene expression profiling can further distinguish DLBCL subgroups with different prognosis. The presence of MYC rearrangement or double hit lymphomas involving MYC and BCL2/BCL6 translocations predicts a very aggressive clinical outcome.
this is powerpoint presentation comprising of latest updates and theory of lymphoma and plasma cell dyscrasias WHO 2016. restricted to all lymphomaniacs.
Downloadable slide decks are a great tool for self study and teaching purposes. They are non-certified resources available to enhance your knowledge.
Review a downloadable slide deck by Sandra E. Kurtin, MS, RN, ANP, AOCN®, covering the most clinically relevant new data reported from The 2012 Oncology Nurse Hematology Conference.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, surgical oncologists, APNs, RNs, pharmacists, managed care pharmacy directors, pathologists, medical directors, allied health professionals, and other physicians affiliated with medical facilities treating patients with head and neck cancers (HNC).
Format: Microsoft PowerPoint (.ppt) | File size: 10.1 MB | Date posted: 4/19/2012
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of April 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CE provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
General information about DLBCL treatment and care for internists. Not meant for hematologist, though.
Sorry for lagging of explanation but what in the slide should be sufficient.
this is powerpoint presentation comprising of latest updates and theory of lymphoma and plasma cell dyscrasias WHO 2016. restricted to all lymphomaniacs.
Downloadable slide decks are a great tool for self study and teaching purposes. They are non-certified resources available to enhance your knowledge.
Review a downloadable slide deck by Sandra E. Kurtin, MS, RN, ANP, AOCN®, covering the most clinically relevant new data reported from The 2012 Oncology Nurse Hematology Conference.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, surgical oncologists, APNs, RNs, pharmacists, managed care pharmacy directors, pathologists, medical directors, allied health professionals, and other physicians affiliated with medical facilities treating patients with head and neck cancers (HNC).
Format: Microsoft PowerPoint (.ppt) | File size: 10.1 MB | Date posted: 4/19/2012
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of April 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CE provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
General information about DLBCL treatment and care for internists. Not meant for hematologist, though.
Sorry for lagging of explanation but what in the slide should be sufficient.
diffuse large B cell lymphoma recent molecular classification
molecular classification and their time frame with references
Recent advantages of DLBCL and thier implication in therapy
Diffuse Large B-cell Lymphoma (DLBCL) is a highly heterogeneous cancer of B cells. Apart from cell-of-origin, genetic variations have been observed to contribute towards heterogeneity leading to different pathogenic mechanisms and overall survival outcomes. Various classification schemes have been proposed that may aid in risk stratification and developing new therapeutics for those who fail frontline therapy. This mini review highlights the significance of genetic variations as biomarkers for DLBCL and ease in extending it to clinical setting.
an update of lymphoma classification for practicing pathologists, hematologists, oncologists, residents, and fellows; important for the prognosis and treatment of lymphoma patients.
Newer biomarkers,techniques & their inclusion in 2016 WHO classification for leukaemia/lymphomas increases the responsibility of the pathologists, requiring to develop an integrated multidisciplinary approach for reporting.
Proteomics Exploration of Chronic Lymphocytic Leukemia_Crimson PublishersCrimsonpublishersCancer
Chronic Lymphocytic Leukemia (CLL) is an adult heme malignancy characterized by the presence of mature-appearing CD5+ B cells in the blood, bone marrow, and secondary lymphoid organs [1]. In the United States, there will be an estimate of 20,720 new cases and 3,930 deaths according to the American Cancer Society statistics. Symptoms include swollen lymph nodes, frequent infections, and fatigue which negatively impacts the quality of life of people affected [1]. CLL is heterogeneous in its progression and clinical outcomes. Factors that contribute to the heterogeneity include the immunoglobulin heavy chain (IGHV) status and chromosomal aberrations [2,3]. There are two subtypes of CLL: Unmutated(U-CLL) and Mutated CLL(M-CLL). 40% and 60% of patients are diagnosed with unmutated and mutated CLL. U-CLL is characterized by the presence of CLL cells that have less than two percent of their IGHV mutated, whereas M-CLL cells have more than two percent mutated [4]. U-CLL is the more aggressive phenotype [2]. These cells have increased responsiveness to antigens that bind the B cell receptor (BCR) versus M-CLL cells [5]. M-CLL is the more indolent phenotype. Increased BCR signaling results in increased cell survival and proliferation [5].
Similar to LLA 2011 - L. Mazzucchelli - Principles of pathology and microscopic diagnosis of lymphoma (20)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
LLA 2011 - L. Mazzucchelli - Principles of pathology and microscopic diagnosis of lymphoma
1. Principles of pathology and microscopic. The paradigm of diffuse large B cell lymphoma Luca Mazzucchelli Istituto cantonale di patologia, Locarno ESO Course, Leukaemia and Lymphoma, Ascona, June 12-14, 2011
8. Diffuse large B-cell lymphoma A Alizadeh AA et al.: Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503
9. Decision tree for classification of DLBCL based on immunohistochemistry CD10 MUM1 bcl6 GCB GCB Non-GCB Non-GCB + + + - - - Hans et al. Blood 2004
10.
11. Gene expression-based distinction of DLBCL in subgroups Gene expression-based distinction between GCB and ABC DLBCL carried a prognostic impact in the CHOP and R-CHOP treatment era Lenz G et al. N Engl J Med 2008; 359:2313
12. Clin Cancer Res 2009; 15:5494 Concordance rate with GEP of 93% versus 86%
13. CHOP R-CHOP GEP New Algorithm Overall Srvival Overall Srvival Clin Cancer Res 2009; 15:5494
14. Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. G Ott et al. Blood 2010, prepublished online August 24 Extension of the study published in Heamatologica 2009; 15:5494 Immunoblastic lymphoma Immunoblastic lymphoma with plasmablastic features
15. G Ott et al. Blood 2010, prepublished online August 24
16. G Ott et al. Blood 2010, prepublished online August 24
17.
18.
19.
20.
21. J Clin Oncol 2010; 28:3360 Univariate Kaplan-Maier analysis of overall survival in the MYC-R versus non rearranged patients
31. DLBCL BL Burkit-like lymphoma Atypical Burkitt lymphoma Gray-zone lymphoma B-cell lymphoma unclassifiable Borderline lymphoma Intermediate between DLBCL and BL (WHO 2008) This is a heterogeneous category that is not considered a distinct disease entity, but is useful in allowing the classification of cases not meeting criteria for classical BL or DLBCL
32. Adv Anat Pathol 2011, 18:219-228 Lymphoma MYC Rearrangement BL Present in >90% of cases; Primary genetic event. Translocations involve Ig partner genes only: 85% t(8;14), 15% t(2;8) or t(8;22). Not associated with “double hit” lymphoma DLBCL Present in 7-14% of de novo cases. Usually a secondary genetic event. Translocations involve IG (70%) and non-IG (30%) partner genes. Associated with “double hit” lymphoma BCLU Present in 35-50% of cases. Translocations rarely involve IGH as a partner gene. Translocations involve IGk , IG or non-IG partner genes. Associated with “double hit” lymphoma PBL Present in approximately 50% of cases. Translocations involve IG partner genes in the majority of cases, usually IGH . Not associated with “double hit” lymphoma
33. Proposed algorithm for highly aggressive lymphomas Cogliatti S et al. Br J Heamatol 2006; 134:294 (modified) Burkitt lymphoma MYC+ DLBCL Intermediate lymphoma Intermediate lymphoma